Addictions are chronic brain diseases that can be treated medically
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
We are headquartered in Santa Monica, with additional offices in London, UK.
Statistics
Patient population with addictions and drug overdose
Over 20 million people are affected by addictions and drug overdose in the United States.
with emergency room visits with Acute Cannabinoid Overdose
with Alcohol Use Disorder
with Opioid Use Disorder and 48k opioid-related overdose deaths annually
PIPELINE
Our pipeline
In response to a growing public health need, Opiant is developing products to treat addictions and drug overdose.
Spotlight
The latest from Opiant
Opioid epidemic was made ‘much worse’ during pandemic
June 30, 2021 – Speaking with Maria Bartiromo on Fox Business News, Dr. Roger Crystal, CEO of Opiant Pharmaceuticals and inventor of the NARCAN® nasal spray, says the best way to combat the opioid epidemic is to reduce demand and previews a new opioid rescue medicine.
American and an opioid overdose crisis – The Watch List
April 19, 2021 – Opiant CEO Roger Crystal on The Watch List to discuss the state of the opioid crisis and an overview of Opiant’s mission to treat addictions and drug overdose.
Confronting a deadlier opioid epidemic – Varney & Co, Fox Business
May 20, 2021 – Opiant CEO Roger Crystal speaks Stuart Varney on Fox Business about the need to confront an opioid epidemic now more deadly from illicit synthetic opioids, incl. fentanyl.
Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
SANTA MONICA, Calif. , July 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and…
Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SANTA MONICA, Calif. , July 20, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
Mr. Ruth led the highly successful launch and commercialization of the first FDA-approved nasal naloxone spray to treat opioid overdose He joins Opiant at a time…
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.
Lessons from a doctor and CEO on the US’s opioid crisis
April 14, 2020 – Roger Crystal set out to impact healthcare at a ‘societal’ level. The doctor who developed the NARCAN® Nasal Spray says he is proud to see its impact on the opioid crisis in the United States: the opioid overdose reversal medicine has saved a large number of lives.
Opiant donates to organizations supporting patients vulnerable to substance use disorders during COVID-19
Opiant donated $40,000 to the International Association of Fire Fighters Foundation, the Association of Recovery in Higher Education, the Harm Reduction Coalition and the UK’s Action on Addiction.
A Prescription for Tackling the Opioid Overdose Crisis – A Panel Discussion
Although the opioid crisis has resulted in close to 600,000 deaths since 1999, evidence shows that increasing the availability of naloxone—a prescription medication that reverses the respiratory depression caused by an opioid overdose—reduces the rate of opioid overdose deaths.